In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 5 II, 1999, Pages 816-822

  Aziz, Imran ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Airways; Albuterol; Antagonism; Asthma; Bronchoprotection; Formaterol; Methacholine; Polymorphism; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; FORMOTEROL; IPRATROPIUM BROMIDE; METHACHOLINE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HUMAN; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TACHYPHYLAXIS;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ARGININE; BRONCHI; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HOMOZYGOTE; HUMANS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; MUSCLE CONTRACTION; POLYMORPHISM, GENETIC; SPIROMETRY;

EID: 0033052542     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70425-2     Document Type: Article

References (27)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
2. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
3. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
4. National Asthma Education and Prevention Programme. Expert Panel report II: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997. Publication no 97-4051.
5. British Thoracic Society. Guidelines on the management of asthma. Thorax 1997;52(suppl 1):S1-21.
6. 2-adrenoceptor agonist salmeterol on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-203.
7. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
8. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic β-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995;50:497-504.
9. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with formoterol in patients with asthma. Am J Med 1994;97:29-37.
10. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996;109:953-6.
11. 2-agonist. Am J Respir Crit Care Med 1996;154:1603-7.
12. Lipworth BJ, Aziz I. A high dose of albuterol does not overcome subsensitivity in asthmatic patients receiving regular salmeterol or formoterol. J Allergy Clin Immunol. 1999;103:88-92.
13. 2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998;11:583-8.
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
15. 2- Adrenoceptor polymorphisms are in linkage disequilibrium but are not associated with asthma in adult population. Clin Exp Allergy 1998;28:442-8.
16. American Thoracic Society. Standardisation of Spirometry - update. Am Rev Respir Dis 1987;136:1285-98.
17. Beach JR, Jung CL, Avery HA, Stenton SC, Dennis JH, Walters EH, et al. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and method of assessing response. Thorax 1993;48:239-43.
18. Egbagbe E, Pavord ID, Wilding P, Thompson-Coon J, Tattersfield AE. Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Thorax 1997;52:239-43.
19. 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997;100:261-5.
20. Rabe KF, Jorres R, Novak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993;147:1436-41.
21. Lipworth BJ, Grove A. Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 1997;43:9-14.
22. 2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996;51:54-8.
23. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 1998;80:31-4.
24. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998;104:431-8.
25. 2-Adrenoceptor polymorphism is associated with susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997;350:995-9.
26. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8.
27. 2-Adrenoceptor polymorphisms: Are they clinically important? Thorax 1996;51:351-3.